For NSCLC, this procedure may be combined with similarly designed PCR-based methods of detecting ALK, ROS1, RET, and MET alterations [17,18,47], thus reducing the total cost of molecular testing. This evidence concerns the gene MET and non-small cell lung carcinoma.